These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25866983)

  • 1. Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy.
    Boccia R; Cooper W; O'Boyle E
    J Community Support Oncol; 2015 Feb; 13(2):38-46. PubMed ID: 25866983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R; O'Boyle E; Cooper W
    BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
    Raftopoulos H; Cooper W; O'Boyle E; Gabrail N; Boccia R; Gralla RJ
    Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
    Raftopoulos H; Boccia R; Cooper W; O'Boyle E; Gralla RJ
    Future Oncol; 2015 Sep; 11(18):2541-51. PubMed ID: 26289588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron.
    Ottoboni T; Gelder MS; O'Boyle E
    J Exp Pharmacol; 2014; 6():15-21. PubMed ID: 27186139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
    Schnadig ID; Agajanian R; Dakhil C; Gabrail NY; Smith RE; Taylor C; Wilks ST; Schwartzberg LS; Cooper W; Mosier MC; Payne JY; Klepper MJ; Vacirca JL
    Future Oncol; 2016 Jun; 12(12):1469-81. PubMed ID: 26997579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials.
    Gabrail N; Yanagihara R; Spaczyński M; Cooper W; O'Boyle E; Smith C; Boccia R
    Cancer Manag Res; 2015; 7():83-92. PubMed ID: 25834466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial.
    Schnadig ID; Agajanian R; Dakhil C; Gabrail N; Vacirca J; Taylor C; Wilks S; Braun E; Mosier MC; Geller RB; Schwartzberg L; Vogelzang N
    Cancer Manag Res; 2017; 9():179-187. PubMed ID: 28579832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
    Barnes M; Calcanes G; Mosier MC; Vacirca J; Malik Z
    Am Health Drug Benefits; 2021 Dec; 14(4):133-139. PubMed ID: 35261717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
    Barnes M; Calcanes G; Mosier MC; Vacirca J; Malik Z
    Am Health Drug Benefits; 2021 Sep; 14(3):1-7. PubMed ID: 35261710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Deeks ED
    Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C; Gayle J; Balu S; Buchner D
    J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
    Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children.
    Patil V; Prasada H; Prasad K; Shenoy UV
    J Community Support Oncol; 2015 Jun; 13(6):209-13. PubMed ID: 26270519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.